InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (16 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
16
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by DeLong Mark Jeffrey, Chief Business & Strat Officer. Officer active across 2 companies, notably Apellis Pharmaceuticals, Inc.. Cumulatively, 44 disclosures have been recorded. Breakdown: 0 buy · 16 sells. Total volume traded: €1.6m. History available since 18 May 2021. The latest transaction was filed on 11 February 2026 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to DeLong Mark Jeffrey
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations44 total
114,591 sharesCommon StockSEC:0001193125-26-224597:0
368 shares@ US$22.15370.3% of flowCommon StockSEC:0001492422-26-000083:0
36,606 shares0Common StockSEC:0001492422-26-000077:0
3,371 shares@ US$21.76542.7% of flowCommon StockSEC:0001492422-26-000059:0
1,334 shares@ US$19.79291.0% of flowCommon StockSEC:0001492422-26-000043:0
1,780 shares@ US$22.18721.4% of flowCommon StockSEC:0001492422-26-000030:0
363 shares@ US$28.53880.4% of flowCommon StockSEC:0001127602-25-004328:0
365 shares@ US$29.52360.5% of flowCommon StockSEC:0001127602-25-002373:0
1,396 shares@ US$30.42551.8% of flowCommon StockSEC:0001127602-25-001831:0
1,235 shares@ US$29.95821.6% of flowCommon StockSEC:0001127602-25-001616:0
28,508 shares0Common StockSEC:0001127602-25-001616:1
1,599 shares@ US$28.70212.0% of flowCommon StockSEC:0001127602-25-001185:0
5,201 shares@ US$13.852.9% of flowCommon StockSEC:0001127602-24-022070:0
9,913 shares@ US$56.9022.9% of flowCommon StockSEC:0001127602-24-010605:0
597 shares@ US$67.76691.7% of flowCommon StockSEC:0001127602-24-004711:0
367 shares@ US$64.13821.0% of flowCommon StockSEC:0001127602-24-002734:0
1,384 shares@ US$64.9963.7% of flowCommon StockSEC:0001127602-24-001931:0
16,963 shares0Common StockSEC:0001127602-24-001438:0
131 shares@ US$46.03620.3% of flowCommon StockSEC:0001127602-23-026187:0
5,280 shares0Common StockSEC:0000899243-23-005788:0
670 shares@ US$51.211.4% of flowCommon StockSEC:0001127602-23-005137:0
367 shares@ US$52.770.8% of flowCommon StockSEC:0001127602-23-002674:0
1,149 shares@ US$52.052.4% of flowCommon StockSEC:0001127602-23-002126:0
19,634 shares0Common StockSEC:0001127602-23-001492:0
196 shares@ US$58.000.5% of flowCommon StockSEC:0001127602-22-024301:0
25 of 44 declarations
About DeLong Mark Jeffrey
DeLong Mark Jeffrey is Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc. He has 44 filings in total, and across the 44 sampled filings from 2021-05-19 to 2026-05-14, the sell amount is EUR 1646319 and the modal transaction nature is Cession.
